Skip to main content
SpringerLink
Log in

Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor

  • Chapter
  • First Online:
Small Molecules in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 201))

Abstract

Bosutinib (SKI-606) is a 4-anilino-3-quinoline carbonitrile, which acts as a dual inhibitor of Src and ABL kinases. In addition, the BCR-ABL fusion gene product, a constitutively activated tyrosine kinase which is crucial for the development of chronic myeloid leukemia (CML), is highly sensitive to bosutinib. Interestingly, distinctly lower concentrations of bosutinib are required to ablate BCR-ABL phosphorylation when compared to the first-generation tyrosine kinase inhibitor imatinib (IM). Bosutinib is a potent inhibitor of CML cell proliferation in vitro and has demonstrated promising activity in CML patients resistant or intolerant to IM as well as in newly diagnosed patients with chronic phase CML (CML-CP). Remarkably, bosutinib has been found to be capable of overcoming the majority of IM-resistant BCR-ABL mutations. Bosutinib has the potency to induce deep and fast responses in second- and third-/fourth-line treatment, and as a consequence, the drug has recently been licensed for patients previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options. Due to its potency and differing toxicity profile, it promises to be a good therapeutic option for a defined cohort of patients. The most common side effects are gastrointestinal with most of the patients suffering from nausea, vomiting, or diarrhea. For the most part, these gastrointestinal symptoms occur early after treatment initiation, are manageable, and often self-limiting. Continuous monitoring of liver enzymes upon treatment initiation is necessary during bosutinib treatment. In addition to CML treatment, bosutinib has shown some efficacy in selected patients suffering from advanced-stage solid tumors. In conclusion, bosutinib is a promising novel small molecule inhibitor approved now for targeted therapy of CML and in clinical development for other malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Baccarani M, Cortes J et al (2013) European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013 Blood 2013 prepublished online 26 June 2013. doi:10.1182/blood-2013-05-501569

  • Bartolovic K, Balabanov S et al (2004) Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103(2):523–529

    Article  CAS  PubMed  Google Scholar 

  • Boschelli DH, Ye F et al (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Srckinaseactivity. J Med Chem 44(23):3965–3977

    Article  CAS  PubMed  Google Scholar 

  • Boschelli F (2008) Activity of bosutinib, dasatinib, and nilotinibagainst 18 imatinib-resistantBcr/Ablmutants. doi:10.1200/JCO.2008.19.8853

  • Bruemmendorf TH, Kantarjian HM et al (2012) Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120:69

    Google Scholar 

  • Bruemmendorf TH, Gambacorti-Passerini C et al (2013) Efficacy and Safety of bosutinib for Philadelphia chromosome-positive leukaemia in older versus younger patients. J Clin Oncol ASCO Annual Meeting abstract, 2013 (suppl; abstr 6511)

    Google Scholar 

  • Campone M, Bondarenko I et al (2012) Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol 23(3):610–617

    Google Scholar 

  • Chung SW, Daniel R et al (1996) The ABL genes in normal and abnormal cell development. CritRevOncog 7(1–2):33–48

    CAS  Google Scholar 

  • Coluccia AM, Benati D et al (2006) SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp 60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 66(4):2279–2286

    Article  CAS  PubMed  Google Scholar 

  • Cortes JE, Kantarjian HM et al (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17):4567–4576

    Article  CAS  PubMed  Google Scholar 

  • Cortes JE, Kim D-W et al (2012) Bosutinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia; results from the BELA trial. J Clin Oncol 30(28):3486–3492

    Article  CAS  PubMed  Google Scholar 

  • Daud AI, Krishnamurthi SS et al (2012) Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 18(4)

    Google Scholar 

  • Donato NJ, Wu JY et al (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2):690–698

    Article  CAS  PubMed  Google Scholar 

  • Gleixner KV, Mayerhofer M et al (2011) KIT-D816V–independant oncogenic signalling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 118(7):1885–1898

    Article  CAS  PubMed  Google Scholar 

  • Golas JM, Arndt K et al (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63(2):375–381

    CAS  PubMed  Google Scholar 

  • Golas JM, Lucas J et al (2005) SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 65(12):5358–5364

    Article  CAS  PubMed  Google Scholar 

  • Greuber EK, Smith-Pearson P, Wang J, Pendergast AM et al. (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13(8):559–571. doi:10.1038/nrc3563

  • Hanfstein B, Mueller C et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26(9):2096–2102

    Article  CAS  PubMed  Google Scholar 

  • Hegedus C, Özvegy-Laczka C et al (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158(4):1153–1164

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hu Y, Swerdlow S et al (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 103(45):16870–16875

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Jallal H, Valentino ML et al (2007) A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 67(4):1580–1588

    Article  CAS  PubMed  Google Scholar 

  • Johnson FM, Gallick GE (2007) SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651–659

    Article  CAS  PubMed  Google Scholar 

  • Khoury JH, Cortes JE et al (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119(15):3403–3412

    Article  CAS  PubMed  Google Scholar 

  • Konig H, Holyoake TL, Bhatia R (2008) Effective and selective inhibition of chronic myeloid leukemia primitive hematopoetic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111(4):2329–2338

    Google Scholar 

  • Laneuville P (1995) Abl tyrosine protein kinase. Semin Immunol 7(4):255–266

    Google Scholar 

  • Levinson NM, Boxer SG et al (2012) Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One 7(4):e29828

    Google Scholar 

  • Li S (2008) Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 49(1):19–26

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lutz MP, Esser IB et al (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243(2):503–508

    Article  CAS  PubMed  Google Scholar 

  • Mazurenko NN, Kogan EA et al (1992) Expression of pp 60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 28(2–3):372–377

    Article  CAS  PubMed  Google Scholar 

  • Mueller MC, Cross NCP et al (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23:1957–1963

    Article  CAS  Google Scholar 

  • Ottenhoff-Kalff AE, Rijksen G et al (1992) Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52(17):4773–4778

    CAS  PubMed  Google Scholar 

  • Pendergast AM (1996) Nuclear tyrosine kinases: from Abl to WEE1. Curr Opin Cell Biol 8(2):174–181

    Article  CAS  PubMed  Google Scholar 

  • Ptasznik A, Nakata Y et al (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10(11):1187–1189

    Article  CAS  PubMed  Google Scholar 

  • Puttini M, Coluccia AM et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66(23):11314–11322

    Article  CAS  PubMed  Google Scholar 

  • Redaelli S, Boschelli F et al (2010) Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib. Leukemia 24(6):1223–1227

    Article  CAS  PubMed  Google Scholar 

  • Redaelli S, Mologni L et al (2012) Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 87(11):E125–E128. doi:10.1002/ajh.23338. Epub 2012 Oct 9

    Google Scholar 

  • Remsing LLR, Rix U et al (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23(3):477–485

    Article  Google Scholar 

  • Sattler M, Griffin JD (2003) Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40(2 Suppl 2):4–10

    Article  CAS  PubMed  Google Scholar 

  • Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337–358

    Article  CAS  PubMed  Google Scholar 

  • Sweeney WE, von Vigier RO (2008) Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 19:1331–1341

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513–609

    Article  CAS  PubMed  Google Scholar 

  • Verbeek BS, Vroom TM et al (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemicalanalysis. J Pathol 180(4):383–388

    Article  CAS  PubMed  Google Scholar 

  • Vultur A, Buettner R et al (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7(5):1185–1194

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zhang J, Kalyankrishna S et al (2007) SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366–376

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology and Stem Cell Transplantation, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany

    Susanne Isfort, Steffen Koschmieder & Tim H. Brümmendorf

  2. Department of Oncology and Hematology, Hubertus Wald Tumorzentrum-Universitäres Cancer Center Hamburg (UCCH), Martinistraße 52, 20246, Hamburg, Germany

    Gunhild Keller-v. Amsberg & Philippe Schafhausen

Authors
  1. Susanne Isfort
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gunhild Keller-v. Amsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philippe Schafhausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steffen Koschmieder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tim H. Brümmendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tim H. Brümmendorf .

Editor information

Editors and Affiliations

  1. Cancer Center Heilbronn-Franken, SLK-Kliniken Heilbronn GmbH Medizinische Klinik III, Heilbronn, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Isfort, S., Amsberg, G.Kv., Schafhausen, P., Koschmieder, S., Brümmendorf, T.H. (2014). Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54490-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54490-3_4

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54489-7

  • Online ISBN: 978-3-642-54490-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation